Related Experiment Video
Updated: May 21, 2025
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Comprehensive analysis of the immunological implication and prognostic value of MEAK7 in non-small cell lung cancer
1Westlake Innovation Capital, Hangzhou, China.
Background:
The mechanistic target of rapamycin (mTOR)-associated protein Eak-7 homolog (MEAK7) is widely involved in the occurrence and development of various diseases, including tumors. However, the role of MEAK7 in non-small cell lung cancer (NSCLC) and its underlying mechanism in the tumor microenvironment remain unclear. The purpose of this paper is to explore the role of MEAK7 in the prognosis of NSCLC.
Methods:
The expression levels of MEAK7 were examined through the utilization of The Cancer Genome Atlas (TCGA) and the genotype-tissue expression project's pan-cancer dataset. Within this context, the relationships between MEAK7 expression and various clinical features, as well as patient outcomes, were assessed using a comprehensive array of bioinformatics resources. Additionally, the link between MEAK7 expression and the infiltration of immune cells was investigated employing CIBERSORT and ESTIMATE methodologies. Gene set enrichment analysis was performed to determine immune responses. Finally, the patient response to immunotherapy was predicted using the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm and immune checkpoint score.
Results:
MEAK7 was highly expressed in many types of tumors including lung adenocarcinoma and lung squamous cell carcinoma. Elevated MEAK7 expression was found to correlate with several key characteristics, including sex, age, the presence of metastasis, and pathological staging, and was identified as a significant predictor of poor prognosis in individuals with lung cancer. Subsequent analyses revealed a positive association between heightened MEAK7 levels and the infiltration of immune cells, as well as the expression profiles of a variety of immune cell markers. MEAK7 was closely linked to the pathways involved in immune regulation. Interestingly, patients with elevated MEAK7 expression levels were sensitive to immunotherapy.
Conclusions:
These findings provide compelling evidence that MEAK7 may be involved in the progression of lung cancer and become a potential therapeutic target.
Insights
Mechanistic target of rapamycin (mTOR)-associated protein Eak-7 homolog (MEAK7) is highly expressed in non-small cell lung cancer (NSCLC), correlating with poor prognosis and immune cell infiltration. Elevated MEAK7 indicates sensitivity to immunotherapy, suggesting it as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Mechanistic target of rapamycin (mTOR)-associated protein Eak-7 homolog (MEAK7) is implicated in various diseases, including cancers.
- The specific role and mechanism of MEAK7 in non-small cell lung cancer (NSCLC) and its tumor microenvironment are not well understood.
Purpose of the Study:
- To investigate the role of MEAK7 in the prognosis of non-small cell lung cancer (NSCLC).
- To explore the underlying mechanisms of MEAK7 in the NSCLC tumor microenvironment.
Main Methods:
- Utilized The Cancer Genome Atlas (TCGA) and genotype-tissue expression (GTEx) datasets to analyze MEAK7 expression.
- Assessed correlations between MEAK7 expression, clinical features, and patient outcomes using bioinformatics resources.
- Investigated MEAK7's relationship with immune cell infiltration (CIBERSORT, ESTIMATE) and predicted immunotherapy response (TIDE).
Main Results:
- MEAK7 was highly expressed in lung adenocarcinoma and lung squamous cell carcinoma, correlating with poor prognosis, metastasis, and advanced staging.
- Elevated MEAK7 expression was associated with increased immune cell infiltration and immune regulatory pathways.
- Patients with high MEAK7 expression showed sensitivity to immunotherapy.
Conclusions:
- MEAK7 plays a significant role in NSCLC progression.
- MEAK7 is a potential predictive biomarker for immunotherapy response in NSCLC.
- MEAK7 represents a promising therapeutic target for NSCLC treatment.
More Related Videos
09:32Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
